Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
•
Primary Care
How long should T3 be continued in hypothyroid patients who received no symptomatic benefit after starting T3/T4 combination therapy?
Answer from: at Community Practice
I stop at next visit and increase T4 replacement accordingly.
Sign in or Register to read more
Answer from: at Community Practice
If no side effects, I ask them to continue it until 6-12 weeks before fully stopping it. Sometimes, they notice they were better with it after they stop it. But most just stop it.
Sign in or Register to read more
19606
20297
Related Questions
How do you counsel patients with elevated Thyroglobulin Peroxidase antibody levels, diffuse thyroiditis features on ultrasound, non-specific symptoms of fatigue, but normal biochemical thyroid function labs?
Would you increase or maintain the same initial dose of methimazole for treatment of hyperthyroidism if symptoms and thyroid tests improve but are not normalized?
What workup do you recommend for patients requiring higher-than-expected levothyroxine doses for their weight?
How soon after radioactive iodine therapy for hyperthyroidism should Methimazole be resumed?
Do SSRIs affect the absorption of Levothyroxine therapy when taken concomitantly?
Do you recommend checking both TSI and TBII antibodies for Graves' disease diagnosis and monitoring?
Would you recommend changing a patient from the pill form of levothyroxine to Tirosint-SOL if they are started on a proton pump inhibitor?
How often should TSH levels be monitored in patients with a history of Graves' disease who are in remission with negative TSI/TBII antibodies and off medical therapy?
How do you assess and adjust treatment in patients who develops hypothyroidism after being on lithium for several years?
What factors would lead you to extend the duration of antithyroid drug therapy in a patient with Graves' disease who is clinically euthyroid at 12 months but has risk factors for recurrence?